Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

• Status: Completed
• Trial end date: 2019-07-17
• Target enrollment: 0
• Participant gender: Female

Summary

Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

1. vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age;

2. diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of > 300mg per 24 hour period or > 1+ on dipstick).

3. patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis)

Exclusion Criteria:

1. abnormal placentation (previa, accreta, etc)

2. antenatal hemorrhage

3. contraindication to oxytocin